Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 91 to 105 of 272 results for carcinoma

  1. Interstitial photodynamic therapy for malignant parotid tumours (HTG166)

    Evidence-based recommendations on interstitial photodynamic therapy for malignant parotid tumours. This involves injecting a photosensitising agent into a vein and using a special light to activate it and destroy the tumour cells.

    HealthTech guidance
    Published
    23 April 2008
    View recommendations

    Sections for HTG166

  2. Epidermal radiotherapy using rhenium-188 paste for non-melanoma skin cancer (HTG714)

    Evidence-based recommendations on epidermal radiotherapy using rhenium-188 paste for non-melanoma skin cancer. This involves radioactive paste being spread on foil over the top of the cancer, to destroy the cancer cells.

    HealthTech guidance
    Published
    2 April 2024
    View recommendations

    Sections for HTG714

  3. Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]

    In development Reference number: GID-TA11116 Expected publication date:  11 November 2026

    Technology appraisal guidance
    In development

  4. Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma [TSID10736]

    Awaiting development Reference number: GID-TA11076 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Image-guided percutaneous laser ablation for primary and secondary liver tumours (HTG722)

    Evidence-based recommendations on image-guided percutaneous laser ablation for primary and secondary liver tumours. This involves heating up liver tissue to destroy tumours.

    HealthTech guidance
    Published
    16 May 2024
    View recommendations

    Sections for HTG722

  6. Cosibelimab for treating advanced cutaneous squamous cell carcinoma [ID6663]

    Awaiting development Reference number: GID-TA11883 Expected publication date:  23 September 2027

    Technology appraisal guidance
    Awaiting development

  7. Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]

    In development Reference number: GID-TA10251 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Transoral carbon dioxide laser surgery for primary treatment of oropharyngeal malignancy (HTG337)

    Evidence-based recommendations on transoral carbon dioxide laser surgery for primary treatment of oropharyngeal malignancy. This involves using a laser to cut out the tumour and a small amount of the healthy flesh around it.

    HealthTech guidance
    Published
    27 March 2014
    View recommendations

    Sections for HTG337

  9. Image-guided radiofrequency excision biopsy of breast lesions (HTG198)

    Evidence-based recommendations on image-guided radiofrequency excision biopsy of breast lesions. This involves inserting a probe that uses radiofrequency energy to cut through the breast internally, and removing the lump with a small area of surrounding tissue to test for cancer.

    HealthTech guidance
    Published
    22 July 2009
    View recommendations

    Sections for HTG198

  10. Microwave ablation for primary or metastatic cancer in the lung (HTG609)

    Evidence-based recommendations on microwave ablation for primary or metastatic cancer in the lung in adults. This involves inserting a probe into the lung, through the skin of the chest, to send microwaves into the cancer cells. This produces heat, aiming to destroy the cancer (ablation).

    HealthTech guidance
    Published
    2 February 2022
    View recommendations

    Sections for HTG609

  11. Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma (TA321)

    Evidence-based recommendations on dabrafenib (Tafinlar) for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation.

    Technology appraisal guidance
    Published
    22 October 2014
    View recommendations

    Sections for TA321

  12. Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]

    Technology appraisal Reference number: TA582 Published:  24 May 2019

    Technology appraisal guidance
    In development

  13. Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C (TA507)

    Evidence-based recommendations on sofosbuvir–velpatasvir–voxilaprevir (Vosevi) for treating chronic hepatitis C in adults.

    Technology appraisal guidance
    Published
    21 February 2018
    View recommendations

    Sections for TA507

  14. Early and metastatic HER2-positive breast cancer: subcutaneous trastuzumab (ESNM13)

    Summary of the evidence on subcutaneous trastuzumab for HER2-positive breast cancer to inform local NHS planning and decision-making

    Evidence summary
    Published
    13 March 2013

  15. Endoscopic mastectomy and endoscopic wide local excision for breast cancer (HTG188)

    Evidence-based recommendations on endoscopic mastectomy and endoscopic wide local excision for breast cancer. This involves removing part or all of the breast using special instruments inserted through small cuts in the skin (keyhole surgery).

    HealthTech guidance
    Published
    22 April 2009
    View recommendations

    Sections for HTG188